Investor relations

Founded in early 2007, Quotient Bioscience has completed seven acquisitions in the United Kingdom:

• HFL Limited - January 2007
• Alba Bioscience Limited - August 2007
• GR Micro Limited - September 2007
• BioDynamics Research Limited - February 2008
• Pharmaceutical Profiles Ltd - December 2008
• Edinburgh Clinical Research Facility from Charles River Laboratories - May 2009
• Amersham Radiolabelling Services - June 2009

Quotient Bioscience is seeking to maintain its current rate of growth through a combination of organic and acquisition-led growth, both in Europe and in North America.

Quotient Bioscience is focused on building a global group providing high value-added analytical and safety evaluation services and products for the bioscience industries and sport.

The principal investors in Quotient Bioscience are Paul Cowan (Chairman and Chief Executive Officer), property companies Helical Bar plc, Dencora, TA Associates and the group’s management and employees.